~~<i id='9297EEFEC1'><strike id='9297EEFEC1'><tt id='9297EEFEC1'><pre id='9297EEFEC1'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：explore 2025-09-29 12:23:59 Page View：19454

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： AMAs digital advisors table RPM coding reform proposal, again
Next article： Wildfire smoke exposes gaps in outdoor worker protections

focus

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

In the gardens at Boston Children's Hospital, families find sanctuary

BostonChildren’sHospitalislocatedintheheartofthecity’sbustlingLongwoodmedicalarea.Butwithinthisdense

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

In the gardens at Boston Children's Hospital, families find sanctuary

BostonChildren’sHospitalislocatedintheheartofthecity’sbustlingLongwoodmedicalarea.Butwithinthisdense